On March 27, 2026, Faga Daniel, the director, President, and CEO of (NASDAQ:ANAB), sold 2,570 shares of the company's common stock at approximately $57.91 each. Despite this sale, he still holds 510,564 shares. AnaptysBio is a biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases.
AnaptysBio recently announced a spin-off of its biopharma operations into a new entity, First Tracks Biotherapeutics, Inc. This new company will trade on the Nasdaq under the ticker "TRAX" starting April 20, 2026. Shareholders of AnaptysBio will receive one share of First Tracks Bio for each share they own, as highlighted by the company's announcement.
First Tracks Bio will begin with a cash balance of $180 million, including $80 million from a private placement. The company will focus on next-generation antibody therapeutics targeting immune pathways. This strategic move aligns with AnaptysBio's broader business update, which also includes a $100 million stock repurchase plan.
AnaptysBio continues to manage collaborations with GSK for Jemperli and Vanda for imsidolimab. The company aims to enhance shareholder value, supported by an estimated net cash and investments of $140 million to $145 million. The recent appointment of Susannah Gray to the Board of Directors is expected to bolster the company's financial strategies.
Currently, (NASDAQ:ANAB)'s stock is priced at $56.02, down 2.41% or $1.38. The stock has fluctuated between $55.62 and $58.71 during the trading day. Over the past year, it has seen a high of $68.39 and a low of $15.40. AnaptysBio's market capitalization is approximately $1.61 billion, with a trading volume of about 273,918 shares on the NASDAQ exchange.
